ArticleJACC. Case reports2026
ST-Segment Elevation Myocardial Infarction in a Patient With Myasthenia Gravis After Intravenous Immunoglobulin Infusion.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute coronary syndrome is rare in patients with myasthenia gravis, with only limited literature available. We report an atypical case of ST-segment elevation myocardial infarction (STEMI) that occurred after intravenous immunoglobulin (IVIg) infusion in a patient with myasthenia gravis. CASE SUMMARY: A 36-year-old woman with a longstanding history of myasthenia gravis developed acute chest pain and ST-segment elevation on electrocardiogram after IVIg administration. Emergent coronary angiography revealed total thrombotic occlusion of the left anterior descending artery. Percutaneous coronary intervention with thrombectomy was successfully performed, and stenting was not required. The patient was discharged in stable condition after hospitalization for an additional 17 days. DISCUSSION: This report highlights an atypical case of STEMI in a young patient without conventional atherosclerotic risk factors, presumably triggered by an IVIg infusion. TAKE-HOME MESSAGE: Clinicians should be aware of the potential risk of thrombotic cardiac events associated with IVIg administration during the treatment of myasthenia gravis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.